Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / InSilico Medicine Hong Kong Limited

Clinicaltrial registered12 Nov 2026

InSilico Medicine Hong Kong Limited

12 Nov 2026: Trial registered · A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM9528. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
12 Nov 2026
Title
A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM9528
Conditions
Healthy Subjects (HS)
Phase
Phase 1
Study Type
Interventional
Status
Recruiting
Countries
United Arab Emirates
Country
United Arab Emirates
Reference
NCT07932041
Location
United Arab Emirates
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at InSilico Medicine Hong Kong Limited

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from United Arab Emirates

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.